HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $15
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $23 to $15.
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $23 to $15.